Completed
Adoptive T Cell Therapy: Directing the Immune System against Ovarian Cancer Cells
Class Central Classrooms beta
YouTube videos curated by Class Central.
Classroom Contents
Immunotherapy for Gynecological Cancers
Automatically move to the next video in the Classroom when playback concludes
- 1 Intro
- 2 Five years Survival in Gynecologic Cancers 2005-2011
- 3 Chemotherapy Gynecologic Cancers
- 4 The Cancer-Immunity Cycle-Targeting Opportunities
- 5 Cancer and the Surrounding Tissue (Tumor Microenvironment)
- 6 The Cancer Cell Shield against Attack from the Immune System
- 7 Targeting the PD-L1/PD-1 Immune Checkpoint in Ovarian Cancer
- 8 Immune Check Point Inhibitors targeting PDL1 or PD1
- 9 Complete Response to Nivolumab in two Patients with Platinum Resistant Ovarian Cancer
- 10 Overall Best Response to Nivolumab in Patients with Platinum Resistant Ovarian Cancer
- 11 Effect of HPV targeted Tumor infiltrating T Cells on Cervical Cancer
- 12 Generation of Tumor Associated Antigen specific T Cells via Expression of TCR or CAR
- 13 CAR and TCR Cancer Clinical Trials in the US 1994 - 2014
- 14 Increase in Cell Persistence following lymphodepleting. preconditioning Chemotherapy prior to Adoptive Cell Transfer
- 15 Adoptive T Cell Therapy: Directing the Immune System against Ovarian Cancer Cells
- 16 Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients with Metastatic Synovial Ceil Sarcoma and Melanoma
- 17 Treatment of Patients with Metastatic Synovial Cell Sarcoma with Autologous T Cells Expressing TCRs Specific for NY-ESO-1
- 18 Immunotherapy Trials for Ovarian Cancer Stanford Gynecologic Oncology
- 19 The Clinical Research Group for Gynecologic Oncology Clinical Trials
- 20 Stanford Gynecologic Oncology Service Stanford Women's Cancer Center and Stanford Cancer Institute
